$MCK

A federal judge in West Virginia refused to dismiss claims of manufacturing defect, negligence, and breach of warranty against Sagent Pharmaceuticals and McKesson Medical-Surgical. The lawsuit alleges a contaminated corticosteroid injection led to a woman's toe amputation. The judge dismissed the failure-to-warn claim, citing federal law preemption.

Morgan Stanley updated its 'Vintage Values' portfolio for 2027, adding Alphabet (GOOGL) and Coca-Cola (KO). The 2026 portfolio returned 32.12%, outperforming the S&P 500. The new list includes 15 stocks, with a focus on large-cap quality and growth. Morgan Stanley's strategy emphasizes bottom-up drivers over momentum. Stock reactions were mixed on Monday.

Morgan Stanley updated its 'Vintage Values' stock picks for 2027, including Alphabet, Coca-Cola, and Apple. The 2026 list gained 32.12%, outperforming the S&P 500. The 2027 portfolio focuses on large-cap growth stocks with high quality metrics. Key selections include Alphabet, Coca-Cola, Apple, Dynatrace, Eli Lilly, and others. GOOGL rose 2%, KO fell 1%, and AAPL added 0.8% on Monday.

McKesson (MCK) shares are falling as investors take profits after a recent rally. The rally was driven by higher earnings guidance, a planned 2027 IPO of its Wellverse unit, and optimism around its Precision Medicine Group deal. Despite thin margins and a stretched balance sheet, the company's strong cash flow supports growth and shareholder returns.

McKesson, a medical and pharmaceutical supplier, reported a data breach affecting 6.4 million email addresses and personal records, including protected health information. The hack, claimed by extortion gang ShinyHunters, involved unauthorized access to third-party applications. McKesson, with $359.05 billion in 2025 revenue, is investigating the incident and has not paid the $55 million ransom demanded. The company assured customers that its systems are secure and operational.

Alluvium Asset Management increased its stake in McKesson (MCK) due to strong long-term growth expectations. McKesson's stock was down 12.6% in the quarter but reported earnings in line with expectations. The company provided strong guidance for next year's earnings. McKesson's stock price is $899.56, with a 52-week gain of 29.95%.

RBC Capital analyst Ryan Halsted maintained a Hold rating on McKesson (MCK) with a $845 price target. McKesson has a Strong Buy consensus and $987.75 average price target. Q2 revenue was $105.38B, down from $97.83B last year, with net profit decreasing from $784M to $614M. Insider sentiment is negative, with increased selling activity.

McKesson (MCK) raised its full-year EPS guidance to 13-15% (15-17% excluding prior-year items) and plans to rebrand its Medical-Surgical unit as Wellverse, targeting an IPO in 2H 2027. The company also aims to acquire Precision Medicine Group to expand oncology and biopharma services. Management highlights core operations are tracking ahead, but structural pressures on drug pricing and high leverage remain risks. McKesson projects $502.2B revenue and $6.3B earnings by 2029, implying 6.9% yearly

McKesson (MCK) raised its outlook, citing growth in its Oncology & Multispecialty segment, which saw 33% revenue growth and 41% adjusted operating profit growth in Q1. The company also announced a deal for Precision Medicine Group, expected to be strategically and financially accretive. McKesson's RxTS segment grew 9% in revenue and 13% in adjusted operating profit, with GLP-1-related business accounting for 11% of its revenue. The company plans to invest more in growth, automation, and technolo

McKesson Corp (MCK) SVP, Controller & CAO Rutledge sold 111 shares on 2026-09-08, reducing holdings to 521 shares. Over the past year, Rutledge sold 901 shares with no purchases, part of a broader pattern of 17 insider sells and 0 buys. McKesson, a healthcare services company, trades at $891.45 with a P/E of 23.65, deemed fairly valued by GuruFocus's GF Value.